Clinical pharmacology considerations for the approval of belimumab for the treatment of adult patients with active lupus nephritis: A regulatory perspective. (April 2022)

• Record Type: Journal Article
• Authors: Liu, Tao; Neuner, Rosemarie; Thompson, Aliza; Pottackal, Ginto; Petullo, David; Liu, Jiang; Nikolov, Nikolay; Sahajwalla, Chandrahas; Doddapaneni, Suresh; Chen, Jianmeng
• Is Part Of: Lupus. Volume 31:Number 4(2022)
• Page Start: 424
• Page End: 432
• Publication Date: 2022-04
• Subjects: Lupus nephritis -- systemic lupus erythematosus -- proteinuria; Systemic lupus erythematosus -- Periodicals; 616.772005
• DOI: 10.1177/09612033221079771
• Languages: English
• ISSNs: 0961-2033

Abstract

On 16 December 2020, FDA approved Benlysta® (belimumab) for both the intravenous (IV) and subcutaneous (SC) administration routes for the treatment of adult patients with active lupus nephritis (LN) who are receiving standard therapy. This approval represents the first FDA approved treatment of patients with active LN. The approved IV dosing regimen (10 mg/kg dose Q2W for three doses, then 10 mg/kg Q4W thereafter) was based on a randomized double-blind placebo controlled clinical trial in adult patients with LN. For the approval of the SC dosing regimen (400 mg dose QW for four doses, then 200 mg QW thereafter), efficacy was supported solely by pharmacokinetics (PK) modeling and simulation which estimated a matched steady state average concentration and higher trough concentrations for the SC administration route, for bridging to the efficacy of IV belimumab in adults with LN. The safety and immunogenicity profile of the SC administration route has been assessed in the SLE studies. In a population PK analysis, higher proteinuria was associated with greater belimumab clearance and lower belimumab exposure. In an exposure response analysis, the efficacy of belimumab as evaluated by renal response was mainly driven by patients with lower proteinuria at baseline regardless of other baseline characteristics (e.g. baseline renal function, renal biopsy classification), induction therapies, or belimumab exposure levels (within 10 mg/kg dosing regimen), etc. However, post hoc analyses showed that belimumab had activity in LN patients with higher proteinuria at baseline. There is no adequate information to suggest that a higher dose would provide additional benefit for patients with lower exposure (e.g. higher proteinuria).